These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal. Broderick PA; Hope O; Okonji C; Rahni DN; Zhou Y Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):157-71. PubMed ID: 14687870 [TBL] [Abstract][Full Text] [Related]
8. Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine, and serotonin systems in the rat brain. Chenu F; El Mansari M; Blier P Neuropsychopharmacology; 2013 Jan; 38(2):275-84. PubMed ID: 22871919 [TBL] [Abstract][Full Text] [Related]
9. Effects of 5-HT1B receptor ligands microinjected into the ventral tegmental area on the locomotor and sensitizating effects of cocaine in rats. Przegaliński E; Papla I; Siwanowicz J; Filip M Eur Neuropsychopharmacol; 2004 May; 14(3):217-25. PubMed ID: 15056481 [TBL] [Abstract][Full Text] [Related]
10. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Millan MJ; Brocco M; Gobert A; Dekeyne A Psychopharmacology (Berl); 2005 Feb; 177(4):448-58. PubMed ID: 15289999 [TBL] [Abstract][Full Text] [Related]
11. Consequences of long-term treatment with agomelatine on depressive-like behavior and neurobiological abnormalities in pinealectomized rats. Tchekalarova J; Nenchovska Z; Atanasova D; Atanasova M; Kortenska L; Stefanova M; Alova L; Lazarov N Behav Brain Res; 2016 Apr; 302():11-28. PubMed ID: 26779670 [TBL] [Abstract][Full Text] [Related]
12. Serotonin1B receptors in the ventral tegmental area modulate cocaine-induced increases in nucleus accumbens dopamine levels. O'Dell LE; Parsons LH J Pharmacol Exp Ther; 2004 Nov; 311(2):711-9. PubMed ID: 15226384 [TBL] [Abstract][Full Text] [Related]
13. Injection of the 5-HT2C receptor agonist Ro60-0175 into the ventral tegmental area reduces cocaine-induced locomotor activity and cocaine self-administration. Fletcher PJ; Chintoh AF; Sinyard J; Higgins GA Neuropsychopharmacology; 2004 Feb; 29(2):308-18. PubMed ID: 14666118 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and pharmacological evaluation of a series of the agomelatine analogues as melatonin MT1 /MT2 agonist and 5-HT2C antagonist. Ettaoussi M; Sabaouni A; Pérès B; Landagaray E; Nosjean O; Boutin JA; Caignard DH; Delagrange P; Berthelot P; Yous S ChemMedChem; 2013 Nov; 8(11):1830-45. PubMed ID: 24031039 [TBL] [Abstract][Full Text] [Related]
15. Differential effects of dopaminergic agents on locomotor sensitisation and on the reinstatement of cocaine-seeking and food-seeking behaviour. Dias C; Lachize S; Boilet V; Huitelec E; Cador M Psychopharmacology (Berl); 2004 Oct; 175(4):414-27. PubMed ID: 15064914 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Olié JP; Kasper S Int J Neuropsychopharmacol; 2007 Oct; 10(5):661-73. PubMed ID: 17477888 [TBL] [Abstract][Full Text] [Related]
17. Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action. Millan MJ Ther Adv Psychopharmacol; 2022; 12():20451253221105128. PubMed ID: 35795687 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of agomelatine in epilepsy and epileptic complications. Vimala PV; Bhutada PS; Patel FR Med Hypotheses; 2014 Jan; 82(1):105-10. PubMed ID: 24314750 [TBL] [Abstract][Full Text] [Related]
19. Repeated agouti related peptide (83-132) injections inhibit cocaine-induced locomotor sensitisation, but not via the nucleus accumbens. Alserda E; Adan RAH; Ramakers GMJ Eur J Pharmacol; 2013 Nov; 719(1-3):187-191. PubMed ID: 23872279 [TBL] [Abstract][Full Text] [Related]
20. Cocaine acts on accumbens monoamines and locomotor behavior via a 5-HT2A/2C receptor mechanism as shown by ketanserin: 24-h follow-up studies. Broderick PA; Olabisi OA; Rahni DN; Zhou Y Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):547-57. PubMed ID: 15093963 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]